+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effects of the study medicine PF-07248144 combined with fulvestrant for treating hormone receptor-positive HR-positive, HER2-negative advanced or metastatic breast cancer. This study focuses on patients whose cancer has progressed after prior treatment with cyclin dependent kinase CDK 46 inhibitor-based therapy. HR-positive breast cancer cells grow in response to hormones like estrogen and progesterone, while HER2-negative cells have little or no HER2 protein, which affects cancer growth and spread. Participants are divided into two groups one receives PF-07248144 tablets daily at home in 28-day cycles along with fulvestrant injections given at the clinic. The other group receives everolimus tablets daily combined with the investigators choice of endocrine therapy, either exemestane tablets or fulvestrant injections. The study compares the safety and effects of PF-07248144 plus fulvestrant against these standard treatments. During the study, participants will have regular clinic visits for injections and monitoring. Researchers will assess disease progression and survival, measure tumor response, record any side effects, and perform laboratory tests including ECGs and drug level checks. The main outcome is progression-free survival, tracked for up to two years, while other safety and effectiveness measures will be followed for up to five years. Total participation may extend over several years depending on individual outcomes.

Age: 18Years +All GendersPhase 3
433 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
S

Actively Recruiting

Researchers are evaluating the effects of a study medicine called PF-08634404, given alone or combined with another antibody named ipilimumab, in adults with a type of liver cancer called hepatocellular carcinoma HCC that is locally advanced or has spread to other parts of the body. This study focuses on patients whose cancer cannot be removed by surgery and who have not yet received whole-body treatment for HCC. Participants will receive PF-08634404 either as a single treatment or together with ipilimumab. Both medicines will be given through intravenous IV infusions administered directly into a vein at clinical trial sites. Participants are randomly assigned to receive either the study medicine alone or in combination with the antibody, with dose levels given sequentially. During the study, participants will be monitored for safety and response to treatment, including adverse events and tumor response using standard criteria. Researchers will assess overall response rates, progression-free survival, and other health measures over approximately 24 months. Medical staff will also track blood tests, serum drug levels, and immune responses. Treatment and follow-up visits will include clinical assessments to understand the effects and side effects of these therapies.

Age: 18Years +All GendersPhase 1Phase 2
60 locations
S

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 for adults with locally advanced or metastatic urothelial cancer, a type of bladder cancer that has spread to nearby tissues or other parts of the body. The study aims to evaluate the safety, effectiveness, and behavior of PF-08634404 in the body, as well as how it affects cancer-related markers. This trial includes adults aged 18 and older who have this type of cancer. The study has two groups Cohort A includes participants who have already received treatment and will receive PF-08634404 alone. Cohort B includes participants who have not had prior treatment and will receive PF-08634404 combined with another cancer medicine called enfortumab vedotin. Both treatments are given through intravenous infusion. Treatment continues as long as it benefits the participant and side effects are manageable. Participants will undergo a screening period to confirm eligibility before starting treatment. During the study, they will have regular visits for treatment, health assessments, scans to monitor cancer progress, and laboratory tests. Researchers will measure outcomes such as the cancers response to treatment, side effects, survival, and drug levels in the body. If the cancer worsens but treatment remains helpful and tolerable, participants may continue treatment with agreement from their doctor and the sponsor. The study follows participants for up to approximately three years.

Age: 18Years +All GendersPhase 1Phase 2
184 locations
S

Actively Recruiting

Researchers are evaluating a new medicine called PF-08634404 in adults with advanced Renal Cell Carcinoma RCC, a type of kidney cancer that has spread locally or to other parts of the body. This study aims to assess the safety of PF-08634404 given alone or combined with other anticancer drugs and to observe how the cancer responds. Participants must be adults with locally advanced or metastatic RCC who have not received treatment for advanced kidney cancer before joining. Participants will be randomly assigned to receive one of four treatments PF-08634404 alone, PF-08634404 with ipilimumab, PF-08634404 with axitinib, or PF-08634404 with Casdatifan. All medications are administered through intravenous infusions or tablets as appropriate, given at clinical study sites by trained medical staff. The study includes treatment and evaluation phases lasting up to approximately three years. During the study, participants will have regular assessments including scans following RECIST v1.1 guidelines to measure tumor response. Researchers will monitor treatment safety by tracking adverse events, dose-limiting toxicities, and laboratory test results. Pharmacokinetics and immune response to the study drug will also be evaluated. These measures will continue through treatment and up to 90 days after the last intervention, with follow-up for up to three years to assess overall survival and progression-free survival.

Age: 18Years +All GendersPhase 1Phase 2
183 locations